Covid 19 Research using Clinical Trials (Home Page)
Report for D015428: Myocardial Reperfusion Injury NIH
(Synonyms: Myocardial Reperfusion Injury)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug313 | Convalescent Plasma Transfusion Wiki | 1.00 |
| drug941 | Random Donor Plasma Wiki | 1.00 |
| drug1102 | Supportive Care Wiki | 0.71 |
Correlated MeSH Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D015427 | Reperfusion Injury NIH | 1.00 |
| D014947 | Wounds and Injuries NIH | 0.32 |
| D002318 | Cardiovascular Diseases NIH | 0.26 |
Correlated HPO Terms (1)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.26 |
There is one clinical trial.
Clinical Trials
1 Association of Early Myocardial Injury With Major Adverse Outcomes in Patients With COVID-19
The study will analyze the incidence, clinical outcomes and predictors of myocardial injury in a large patient population with COVID-19 treated in Mount Sinai Hospital (MSH) system. In addition, the study team will explore the association between high-sensitivity troponin I (TnI) levels and clinical characteristics, biomarkers, cardiac tests data and treatment approaches to uncover the potential mechanisms responsible for COVID-19 induced myocardial injury.
NCT04397939 COVID-19 Myocardial Reperfusion Injury Cardiovascular Diseases MeSH:Reperfusion Injury Myocardial Reperfusion Injury Wounds and Injuries Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system
Primary Outcomes
Description: Number of death during hospitalization
Measure: Number of In-Hospital Death Time: During hospitalization, average 2-3 weeks
Secondary Outcomes
Description: Length of stay in the hospital
Measure: Length of Stay Time: During hospitalization, average 2-3 weeks
Description: Successful treatment will be defined by two consecutive negative tests for COVID-19
Measure: Number of Successful Treatment Time: During hospitalization, average 2-3 weeks
HPO Nodes
Primary Outcomes
Description: Number of death during hospitalization
Measure: Number of In-Hospital Death Time: During hospitalization, average 2-3 weeksSecondary Outcomes
Description: Length of stay in the hospital
Measure: Length of Stay Time: During hospitalization, average 2-3 weeksDescription: Successful treatment will be defined by two consecutive negative tests for COVID-19
Measure: Number of Successful Treatment Time: During hospitalization, average 2-3 weeks